Neurocrine Biosciences director sells 15,000 shares

The option exercises and share sales each covered 15,000 shares; a broker made the sales under a Rule 10b5-1 plan adopted May 26, 2026.

Available on EDGAR 11/03/2026 - 06:52 PM EST Accepted by SEC EDGAR 11/03/2026 - 06:52 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Neurocrine Biosciences director George J. Morrow exercised options for 15,000 common shares at $53.64 per share on October 30, November 2 and November 3, 2026, and sold 15,000 shares on those dates. Reported sale prices included $149.00 per share on October 30, $144.9751 on November 2 and $158.18 on November 3. A broker effected the sales under a Rule 10b5-1 trading plan adopted May 26, 2026. The options were scheduled to expire May 22, 2027.

Insider Trade Summary 10b5-1

Exercise and Sale: 15,000 shares ($1.53M approx. pre-tax spread)

Exercise and Sale 18 txns

Insider MORROW GEORGE J

Role Director

Sold 15,000 shs ($2.34M)

Approx. gross sale proceeds $2.34M

Approx. exercise cost $805K

Approx. pre-tax spread $1.53M

Type	Security	Shares	Price	Value
Exercise	Non-Qualified Stock Option F11	7,200	$0.00	$0.00
Exercise	Common Stock	7,200	$53.64	$386K
Sale	Common Stock F1	100	$158.18	$16K
Sale	Common Stock F1	100	$162.05	$16K
Sale	Common Stock F1, F5	600	$163.7083	$98K
Sale	Common Stock F1, F6	1,226	$164.7402	$202K
Sale	Common Stock F1, F7	908	$165.706	$150K
Sale	Common Stock F1, F8	1,466	$166.7748	$244K
Sale	Common Stock F1, F9	1,500	$167.7248	$252K
Sale	Common Stock F1, F10	1,300	$168.5325	$219K
Exercise	Non-Qualified Stock Option F11	7,500	$0.00	$0.00
Exercise	Common Stock	7,500	$53.64	$402K
Sale	Common Stock F1, F2	1,900	$144.9751	$275K
Sale	Common Stock F1, F3	4,300	$145.8591	$627K
Sale	Common Stock F1, F4	1,300	$146.7562	$191K
Exercise	Non-Qualified Stock Option F11	300	$0.00	$0.00
Exercise	Common Stock	300	$53.64	$16K
Sale	Common Stock F1	300	$149.00	$45K

Holdings After Transaction: Non-Qualified Stock Option — 0 contracts (Direct); Common Stock — 10,386 shares (Direct)

Footnotes (11)

1. F1. The dispositions reported in this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on May 26, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
2. F2. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $144.32 to $145.28. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
3. F3. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $145.35 to $146.34. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
4. F4. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $146.38 to $147.26. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
5. F5. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $163.21 to $164.01. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
6. F6. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $164.22 to $165.20. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
7. F7. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $165.26 to $166.24. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
8. F8. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $166.26 to $167.20. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
9. F9. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $167.27 to $168.18. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
10. F10. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $168.27 to $169.10. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
11. F11. The option was granted May 22, 2017 and vested in 12 equal monthly installments beginning June 22, 2017. These options were scheduled to expire on May 22, 2027.

Key Figures

Shares sold: 15,000 shares Common shares acquired through option exercise: 15,000 shares Option exercise price: $53.64 per share +3 more

6 metrics

Shares sold 15,000 shares Across October 30, November 2 and November 3, 2026

Common shares acquired through option exercise 15,000 shares Across October 30, November 2 and November 3, 2026

Option exercise price $53.64 per share Options exercised October 30, November 2 and November 3, 2026

Reported sale price $144.9751 per share 1,900 shares sold November 2, 2026

Rule 10b5-1 plan adoption date May 26, 2026 Plan applicable to the reported sales

Option expiration date May 22, 2027 Scheduled expiration

Key Terms

Non-Qualified Stock Option, Rule 10b5-1 trading plan, weighted average sales price per share

3 terms

Non-Qualified Stock Option financial

"the options exercised for common shares at $53.64 per share"

A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.

Rule 10b5-1 trading plan regulatory

"dispositions were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sales price per share financial

"Represents a weighted average sales price per share"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many NBIX shares did director George J. Morrow sell?

George J. Morrow sold 15,000 shares on October 30, November 2 and November 3, 2026. Reported prices included $149.00 per share on October 30, $144.9751 on November 2 and $158.18 on November 3; a broker carried out the sales under a Rule 10b5-1 plan adopted May 26, 2026.

What options did NBIX director George J. Morrow exercise?

George J. Morrow exercised options for 15,000 common shares at $53.64 per share on October 30, November 2 and November 3, 2026. The options were scheduled to expire May 22, 2027.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MORROW GEORGE J

(Last) (First) (Middle)

6027 EDGEWOOD BEND CT.

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NEUROCRINE BIOSCIENCES INC [ NBIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/30/2026		M		300	A	$53.64	10,686	D
Common Stock	10/30/2026		S(1)		300	D	$149	10,386	D
Common Stock	11/02/2026		M		7,500	A	$53.64	17,886	D
Common Stock	11/02/2026		S(1)		1,900	D	$144.9751(2)	15,986	D
Common Stock	11/02/2026		S(1)		4,300	D	$145.8591(3)	11,686	D
Common Stock	11/02/2026		S(1)		1,300	D	$146.7562(4)	10,386	D
Common Stock	11/03/2026		M		7,200	A	$53.64	17,586	D
Common Stock	11/03/2026		S(1)		100	D	$158.18	17,486	D
Common Stock	11/03/2026		S(1)		100	D	$162.05	17,386	D
Common Stock	11/03/2026		S(1)		600	D	$163.7083(5)	16,786	D
Common Stock	11/03/2026		S(1)		1,226	D	$164.7402(6)	15,560	D
Common Stock	11/03/2026		S(1)		908	D	$165.706(7)	14,652	D
Common Stock	11/03/2026		S(1)		1,466	D	$166.7748(8)	13,186	D
Common Stock	11/03/2026		S(1)		1,500	D	$167.7248(9)	11,686	D
Common Stock	11/03/2026		S(1)		1,300	D	$168.5325(10)	10,386	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option	$53.64	10/30/2026		M			300	(11)	05/22/2027	Common Stock	300	$0	14,700	D
Non-Qualified Stock Option	$53.64	11/02/2026		M			7,500	(11)	05/22/2027	Common Stock	7,500	$0	7,200	D
Non-Qualified Stock Option	$53.64	11/03/2026		M			7,200	(11)	05/22/2027	Common Stock	7,200	$0	0	D

Explanation of Responses:

1. The dispositions reported in this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on May 26, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

2. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $144.32 to $145.28. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

3. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $145.35 to $146.34. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

4. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $146.38 to $147.26. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

5. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $163.21 to $164.01. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

6. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $164.22 to $165.20. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

7. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $165.26 to $166.24. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

8. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $166.26 to $167.20. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

9. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $167.27 to $168.18. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

10. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $168.27 to $169.10. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

11. The option was granted May 22, 2017 and vested in 12 equal monthly installments beginning June 22, 2017. These options were scheduled to expire on May 22, 2027.

Remarks:

	/s/ Darin Lippoldt, Attorney-in-Fact	11/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)